{"id":909361,"date":"2025-11-13T01:03:05","date_gmt":"2025-11-13T06:03:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/"},"modified":"2025-11-13T01:03:05","modified_gmt":"2025-11-13T06:03:05","slug":"innate-pharma-reports-third-quarter-2025-business-update-and-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/","title":{"rendered":"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwuline { text-decoration: underline }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }\n.bwwidth100 { width: 100% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b><i>Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in S\u00e9zary syndrome<\/i><\/b><\/li>\n<li><b><i>IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well &#8211; pharmacologically active dose reached<\/i><\/b><\/li>\n<li><b><i>Monalizumab PACIFIC-9 on track to deliver data in H2 2026<\/i><\/b><\/li>\n<li><b><i>Cash position of \u20ac 56.4 million<sup>1<\/sup> as of September 30, 2025, anticipated cash runway until end Q3-2026<\/i><\/b><\/li>\n<li><b><i>Conference call to be held today at 2:00 p.m. CET \/ 8:00 a.m. ET<\/i><\/b><\/li>\n<\/ul>\n<p>MARSEILLE, France&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegulatory News:<\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201c<b>Innate<\/b>\u201d or the \u201c<b>Company<\/b>\u201d) today announced its business update and financial results for the first nine months of 2025.<\/p>\n<p>\n\u201c<i>This quarter highlights strong execution across our key programs<\/i>,\u201d <b>said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. <\/b>\u201c<i>With FDA clearance to initiate TELLOMAK-3, we are advancing lacutamab toward its confirmatory Phase 3 and potential accelerated approval in S\u00e9zary syndrome. We remain on track for dose-escalation data, from IPH4502, our Nectin-4 ADC, in the first half of 2026, followed by monalizumab PACIFIC-9 results in the second half of 2026. Together, these milestones position us well to deliver meaningful value for patients and shareholders as we continue to advance our differentiated portfolio<\/i>.\u201d<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\">__________________________<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><sup>1<\/sup> Including short term investments (\u20ac6.1 million) and non-current financial instruments (\u20ac10.4 million).<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth100\" rowspan=\"1\" colspan=\"1\">\n<p>\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\"><b><i>Webcast and conference call will be held today at 2:00pm CET (8:00am ET)<\/i><\/b><\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\">\nThe live webcast will be available at the following link:<\/p>\n<p class=\"bwalignc bwcellpmargin\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F424851735&amp;esheet=54357130&amp;newsitemid=20251112563057&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F424851735&amp;index=1&amp;md5=dba5ab3992805b9c3f0186170de5d5a7\">https:\/\/events.q4inc.com\/attendee\/424851735<\/a><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\">\nAnalysts may also join via telephone, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fanalyst%2F424851735%3Fpwd%3D_b%255EEVw8x&amp;esheet=54357130&amp;newsitemid=20251112563057&amp;lan=en-US&amp;anchor=click&amp;index=2&amp;md5=32456dcea11909e98ac82e1375759d0b\">click <\/a><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fanalyst%2F424851735%3Fpwd%3D_b%255EEVw8x&amp;esheet=54357130&amp;newsitemid=20251112563057&amp;lan=en-US&amp;anchor=here+to+register&amp;index=3&amp;md5=baf69a05068a8bd73fd90489825adc79\">here to register<\/a><\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\"><i>This information can also be found on the Investors section of the Innate Pharma website,<\/i><\/p>\n<p class=\"bwalignc bwcellpmargin\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com&amp;esheet=54357130&amp;newsitemid=20251112563057&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=4&amp;md5=7938e7cf0b1f6e1ef8bd3035818f62ca\"><i>www.innate-pharma.com<\/i><\/a><i>. A replay of the webcast will be available on the Company website for 90 days following the event.<\/i><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>Pipeline highlights:<\/b><\/p>\n<p><b>Strategic focus<\/b><\/p>\n<p>\nAs previously announced, Innate Pharma is prioritizing its investment on what it believes are its highest-value clinical assets, IPH4502, lacutamab, and monalizumab (partnered with AstraZeneca); and advancing the next Antibody Drug Conjugates (ADCs) toward development, leveraging its pipeline of innovative targets.<\/p>\n<p><b><span class=\"bwuline\">Lacutamab (anti-KIR3DL2 antibody):<\/span><\/b><\/p>\n<p><span class=\"bwuline\">Cutaneous T Cell Lymphoma<\/span><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe Company announced on November 10 that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), with no further comments, clearing the trial to proceed.<\/p>\n<\/li>\n<li>\nThe planned confirmatory Phase 3 trial, TELLOMAK-3, is an open-label, randomized study designed to demonstrate the efficacy of lacutamab in patients with S\u00e9zary syndrome and Mycosis fungoides, who failed at least one prior line of systemic therapy. The trial will include two independent cohorts: one enrolling patients with S\u00e9zary syndrome post-mogamulizumab treatment randomized 1:1 to receive lacutamab or romidepsin, and one enrolling patients with Mycosis fungoides randomized 1:1 to receive lacutamab or mogamulizumab. The primary endpoint of the study for both cohorts is progression-free survival (PFS) evaluated by blinded central review.<\/p>\n<\/li>\n<li>\nData from the Phase 2 TELLOMAK trial in CTCL demonstrated durable activity, a favorable safety profile, and improvements in patients\u2019 quality of life. With this feedback from FDA, the Company is progressing towards the initiation of the confirmatory Phase 3 TELLOMAK-3 trial in H1 2026. FDA provided encouraging initial feedback on Innate Pharma\u2019s proposed regulatory pathway, which could potentially include Accelerated Approval for S\u00e9zary syndrome, once the Phase 3 trial is underway.<\/p>\n<\/li>\n<li>\nThe Company held a KOL event on October 28, 2025 on lacutamab and provided updates on the planned Phase 3 trial, the regulatory pathway in CTCL, and the commercial opportunity for lacutamab.<\/p>\n<\/li>\n<\/ul>\n<p><span class=\"bwuline\">Peripheral T Cell lymphoma (PTCL)<\/span><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe Phase 2 KILT (anti-KIR in T Cell Lymphoma) trial, an investigator-sponsored, randomized controlled trial led by the Lymphoma Study Association (LYSA) to evaluate lacutamab in combination with chemotherapy GEMOX (gemcitabine and oxaliplatin) versus GEMOX alone in patients with KIR3DL2-expressing relapsed\/refractory PTCL is ongoing and continues to recruit patients.<\/p>\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">IPH4502 (Nectin-4 exatecan ADC):<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe Phase 1 trial will assess the safety, tolerability, and preliminary efficacy of IPH4502 in advanced solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The study plans to enroll approximately 105 patients.<\/p>\n<\/li>\n<li>\nThe first patient was dosed in the Phase 1 study in January 2025. Enrollment of the dose escalation part continues to progress well and is expected to be completed at the end of 2025 or in the first quarter of 2026. Pharmacologically active dose has been reached.<\/p>\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca:<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe Phase 3 PACIFIC-9 trial run by AstraZeneca evaluating durvalumab (anti-PD\u2011L1) in combination with monalizumab or AstraZeneca\u2019s oleclumab (anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who have not progressed following definitive platinum-based concurrent chemoradiation therapy (CRT) is ongoing. Enrollment in the trial is complete, and data readouts are expected in H2 2026.<\/p>\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Other Clinical stage assets<\/span><\/b><\/p>\n<p><b>IPH6501 (ANKET<sup>\u00ae<\/sup> anti-CD20 with IL-2V, proprietary): <\/b>The Phase 1\/2 clinical trial is evaluating IPH6501 in B-cell Non-Hodgkin\u2019s lymphoma (B-NHL). The study is planned to enroll up to 184 patients. Clinical sites are open in the US, Australia, and France. Enrollment in the dose escalation phase of the trial is complete. Clinical data are expected to be presented in 2026.<\/p>\n<p><b>IPH6101 (ANKET<sup>\u00ae<\/sup> anti-CD123, proprietary): <\/b>Innate regained the rights to SAR\u2019579\/IPH6101 in July 2025. Data from the Sanofi-led Phase 1\/2 study and Phase 2 preliminary dose expansion of the trial have been transferred to Innate and the Company is evaluating potential next steps.<\/p>\n<p><b>IPH5201 (anti-CD39 antibody, partnered with AstraZeneca): <\/b>The MATISSE Phase 2 clinical trial conducted by Innate in neoadjuvant lung cancer for IPH5201, an anti CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, is ongoing, and recruitment is on track.<\/p>\n<p><b>IPH5301 (anti-CD73, proprietary): <\/b>The investigator-sponsored CHANCES Phase 1 trial of IPH5301 with Institut Paoli-Calmettes is ongoing.<\/p>\n<p><b>Corporate update<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAs previously announced, in line with its strategic focus, the Company intends to streamline its organization. Planned layoffs will be implemented through a redundancy plan, expected to be completed during the first half of 2026. A consultation with the Workers&#8217; Council is ongoing and the plan is subject to endorsement by the French authorities (Dreets).<\/p>\n<\/li>\n<li>\nThe ATM program, pursuant to which it may, from time to time, offer and sell to eligible investors a total gross amount of up to $75 million of American Depositary Shares (\u201cADS\u201d) is still in place. As of September 30, 2025, no sales have been made under the program.<\/p>\n<\/li>\n<\/ul>\n<p><b>Financial Results<\/b><\/p>\n<p>\nCash, cash equivalents and financial assets of the Company amounted to \u20ac56.4 million as of September 30, 2025. At the same date, financial liabilities amounted to \u20ac24.8 million.<\/p>\n<p>\nRevenues for the first nine months of 2025 amounted to \u20ac2.3 million (\u20ac10.2 million for the same period in 2024). For the nine-month period, ended September 30, 2025, revenue from collaboration and licensing agreements mainly resulted from the partial or entire recognition of the proceeds received pursuant to the agreements with AstraZeneca and Sanofi.<\/p>\n<p><b>About Innate Pharma<\/b><\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.<\/p>\n<p>\nInnate Pharma is advancing a portfolio of differentiated potential first- and\/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.<\/p>\n<p>\nInnate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.<\/p>\n<p>\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n<p>\nLearn more about Innate Pharma at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com&amp;esheet=54357130&amp;newsitemid=20251112563057&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=5&amp;md5=f4cc796038a6f93d3e493016e7c82c20\">www.innate-pharma.com<\/a> and follow us on LinkedIn and X.<\/p>\n<p><b>Information about Innate Pharma shares<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>ISIN code<\/b><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFR0010331421<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Ticker code<\/b><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>LEI<\/b><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>Disclaimer on forward-looking information and risk factors<\/b><\/p>\n<p>\nThis press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, including the statements regarding the timing of dose-escalation data for IPH4502, the timing of results for monalizumab PACIFIC-9, the timing of lacutamab Phase 3 and potential acceleration thereof, the contours and planned enrollment of the upcoming trials and studies, and the planned streamlining of the organization, including layoffs. The use of certain words, including \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201cwill,\u201d or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s reliance on third parties to manufacture its product candidates, the Company\u2019s commercialization efforts and the Company\u2019s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=54357130&amp;newsitemid=20251112563057&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=6&amp;md5=16152808f1158406a3b452f55f9535a9\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.<\/p>\n<p>\nIn light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251112563057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251112563057\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251112563057\/en\/<\/a><\/span><\/p>\n<p><b>For additional information, please contact:<\/b><\/p>\n<p><b>Innate Pharma<br \/>\n<\/b><br \/>St\u00e9phanie Cornen<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:stephanie.cornen@innate-pharma.fr\">stephanie.cornen@innate-pharma.fr<\/a><\/p>\n<p><b>Investor Relations<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:investors@innate-pharma.fr\">investors@innate-pharma.fr<\/a><\/p>\n<p><b>Medias<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:communication@innate-pharma.fr\">communication@innate-pharma.fr<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Maryland Europe United States North America France<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251112563057\/en\/1245155\/3\/INNATEvertnoirDS.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in S\u00e9zary syndrome IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well &#8211; pharmacologically active dose reached Monalizumab PACIFIC-9 on track to deliver data in H2 2026 Cash position of \u20ac 56.4 million1 as of September 30, 2025, anticipated cash runway until end Q3-2026 Conference call to be held today at 2:00 p.m. CET \/ 8:00 a.m. ET MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced its business update and financial results for the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-909361","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in S\u00e9zary syndrome IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well &#8211; pharmacologically active dose reached Monalizumab PACIFIC-9 on track to deliver data in H2 2026 Cash position of \u20ac 56.4 million1 as of September 30, 2025, anticipated cash runway until end Q3-2026 Conference call to be held today at 2:00 p.m. CET \/ 8:00 a.m. ET MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced its business update and financial results for the &hellip; Continue reading &quot;Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-13T06:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251112563057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results\",\"datePublished\":\"2025-11-13T06:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/\"},\"wordCount\":1838,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251112563057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/\",\"name\":\"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251112563057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-11-13T06:03:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251112563057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251112563057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Market Newsdesk","og_description":"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in S\u00e9zary syndrome IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well &#8211; pharmacologically active dose reached Monalizumab PACIFIC-9 on track to deliver data in H2 2026 Cash position of \u20ac 56.4 million1 as of September 30, 2025, anticipated cash runway until end Q3-2026 Conference call to be held today at 2:00 p.m. CET \/ 8:00 a.m. ET MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced its business update and financial results for the &hellip; Continue reading \"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-13T06:03:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251112563057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results","datePublished":"2025-11-13T06:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/"},"wordCount":1838,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251112563057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/","name":"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251112563057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-11-13T06:03:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251112563057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251112563057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2025-business-update-and-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/909361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=909361"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/909361\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=909361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=909361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=909361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}